Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I

Circulation. 2004 Sep 28;110(13):1754-60. doi: 10.1161/01.CIR.0000142671.06167.91. Epub 2004 Sep 20.

Abstract

Background: In a previous substudy of the GUSTO-I trial, we observed better functional and quality-of-life outcomes among patients in the United States (US patients) compared with patients in Canada. Rates of invasive therapy were significantly higher in the United States and were associated with a small mortality benefit (0.4%, adjusted P=0.02). We sought to determine whether Canadian-US differences in practice patterns in GUSTO-I had an impact on 5-year mortality.

Methods and results: Mortality data for 23,105 US and 2898 Canadian patients enrolled in GUSTO-I were obtained from national mortality databases. Median follow-up was 5.46 years in the US and 5.33 years in the Canadian cohort. Five-year mortality rate was 19.6% among US and 21.4% among Canadian patients (P=0.02). After baseline adjustment, enrollment in Canada was associated with a higher hazard of death (1.17; 95% confidence interval, 1.07 to 1.28, P=0.001). Revascularization rates during the index hospitalization in the United States were almost 3 times those in Canada: 30.5% versus 11.4% for angioplasty and 13.1% versus 4.0% for bypass surgery (P<0.01 for both). After accounting for revascularization status as a time-dependent covariate, country was no longer a significant predictor of long-term mortality. These results were confirmed in a propensity-matched analysis.

Conclusions: Our results suggest, for the first time, that the more conservative pattern of care with regard to early revascularization in Canada for ST-segment elevation acute myocardial infarction may have a detrimental effect on long-term survival. Our results have important policy implications for cardiac care in countries and healthcare systems wherein use of invasive procedures is similarly conservative.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty / statistics & numerical data
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use
  • Canada / epidemiology
  • Case Management
  • Cohort Studies
  • Comorbidity
  • Coronary Artery Bypass / statistics & numerical data
  • Drug Therapy, Combination
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Heparin / therapeutic use
  • Humans
  • Injections, Intravenous
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / mortality*
  • Myocardial Infarction / surgery
  • Myocardial Infarction / therapy
  • Myocardial Revascularization / methods
  • Myocardial Revascularization / statistics & numerical data
  • Practice Patterns, Physicians'
  • Proportional Hazards Models
  • Streptokinase / therapeutic use
  • Survival Analysis
  • Thrombolytic Therapy / statistics & numerical data
  • Tissue Plasminogen Activator / therapeutic use
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Heparin
  • Streptokinase
  • Tissue Plasminogen Activator